# Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

> **NCT00714246** · PHASE1 · TERMINATED · sponsor: **Milton S. Hershey Medical Center** · enrollment: 6 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Carboplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00714246
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2019-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00714246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00714246, "Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00714246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*